DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

戻る Press-Releases

DIA's India Annual Meeting to Host Discussions on Evolving Regulatory Landscape

Subcontinent's regulators and stakeholders to also discuss patient safety, compliance, advanced therapies, and emerging technologies' impact on healthcare

MUMBAI — Aug. 2, 2024 — DIA, a global organization of life sciences professionals, will facilitate a series of discussions on the evolving regulatory landscape in India, the transformative power of digitization in healthcare, and how to prioritize patient safety during the DIA India Annual Meeting, which will be held Sept. 24-25 at Novotel Mumbai Juhu Beach.

This year's theme, "Confluence of Care," focuses on the need for widespread cooperation and deliberation to drive the safe and effective implementation of emerging treatments. For the first time, attendees of the India Annual Meeting can choose from three specialized tracks — pharmacovigilance, clinical-regulatory, and medical devices.

"The future of healthcare in India hinges on two critical factors: access and safety," said Dr Ashok Swain, DIA's General Manager, India Operations. "As we work to bring advanced treatments to India's vast and diverse population, we must strengthen our efforts to do more than just treat more patients. We must safeguard every individual's well-being."

Dr Chandrashekar Ranga, the Joint Drugs Controller of India, will discuss the obstacles regulators face in the digital era; Dr. Stewart Geary, the Global Safety Officer at Eisai and a Fellow of DIA, will provide updates on behalf of the Council for International Organizations of Medical Sciences (CIOMS) Working Group XII on Benefit-Risk Balance for Medicinal Products; Amrit Gill, the Global Head of Pharmacovigilance at Sanofi Consumer Healthcare, will address generic label management; and Aman Wasan, CEO at ArisGlobal, will speak on how advanced technology is enabling pharmaceutical research and development.

Sessions will also cover challenges and opportunities in generic drugs, as 20% of all generic medicines are produced in India; the discretionary aspect of clinical evidence for medical devices, which were not regulated in India until 2017; and the proper application of pharmacovigilance practices to popular alternative medicines such as ayurveda, yoga, Unani, Siddha, and homeopathy. The safety of nanoparticles, complexities surrounding medicolegal cases, and long-acting formulations like implants in bioavailability and bioequivalence studies will also be discussed.

"This meeting underscores our commitment to bringing industry representatives, government officials, regulators, academics, and patients together from across India and Southern Asia," said Marwan Fathallah, DIA's President and Chief Executive Officer. "Come learn about the advancements being made in innovative therapies that promise to redefine the boundaries of medical science and improve quality of life."

Now in its 11th year, the India Annual Meeting enables attendees to interact, network, and debate the most pressing issues facing the life sciences. The meeting will continue to serve as a platform for decision-makers to share challenges and opportunities while hearing from experts about their vision for the future.

"Over the last decade, DIA India has undertaken monumental efforts to bring relevant and important stakeholders together to discuss critical issues and emerging risks associated with medicines and seek remedial measures," said Prof. Moin Don, the India Annual Meeting Chair, International Society of Pharmacovigilance (ISoP) South Asia Chapter Lead, and CEO and Founder of PVCON Consulting.

DIA is celebrating 60 years of bringing together leading minds to foster collaboration and advancement in global healthcare. Early-bird registration for the India Annual Meeting is available through Aug. 10. To register or view the event program, click here. Media members can request credentials by emailing diaglobal@gregoryfca.com.

About DIA

DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.

 

Media Contact

Denise DiMeglio
denise@gregoryfca.com
610-228-2102

 

For conference registration-related queries

Nishank Nivedit
nishank.nivedit@diaglobal.org

 

For other queries
Dr Ashok Swain
ashok.swain@diaglobal.org

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。